Clinuvel Pharmaceuticals (ASX:CUV) has enrolled more than 200 patients in its phase III trial of Scenesse in vitiligo in line with its recruitment target, according to a Wednesday filing with the Australian bourse.
The randomized trial is being conducted in 37 study sites across North America, Africa, and Europe. It is assessing Scenesse as a systemic repigmentation therapy for vitiligo patients using the vitiligo area scoring index as the primary endpoint, the filing said.
The trial aims to achieve a minimum of 50% repigmentation across a patient's total body surface area, the filing added. Initial results are expected in the second half of 2026.
Clinuvel Pharmaceuticals' shares were down nearly 1% in recent Wednesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。